Cargando…
Matrix-Associated Autologous Chondrocyte Implantation Is an Effective Treatment at Midterm Follow-up in Adolescents and Young Adults
BACKGROUND: Autologous chondrocyte implantation (ACI) is an established method for treating cartilage defects in the knee of adult patients. However, less is known about its effectiveness in adolescents. HYPOTHESIS: Third-generation matrix-associated ACI (MACI) using spheroids (co.don chondrosphere/...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484242/ https://www.ncbi.nlm.nih.gov/pubmed/31041335 http://dx.doi.org/10.1177/2325967119841077 |
_version_ | 1783414082931523584 |
---|---|
author | Hoburg, Arnd Löer, Ingo Körsmeier, Konrad Siebold, Rainer Niemeyer, Philipp Fickert, Stefan Ruhnau, Klaus |
author_facet | Hoburg, Arnd Löer, Ingo Körsmeier, Konrad Siebold, Rainer Niemeyer, Philipp Fickert, Stefan Ruhnau, Klaus |
author_sort | Hoburg, Arnd |
collection | PubMed |
description | BACKGROUND: Autologous chondrocyte implantation (ACI) is an established method for treating cartilage defects in the knee of adult patients. However, less is known about its effectiveness in adolescents. HYPOTHESIS: Third-generation matrix-associated ACI (MACI) using spheroids (co.don chondrosphere/Spherox) is an effective and safe treatment for articular cartilage defects in adolescents aged 15 to 17 years, with outcomes comparable with those for young adults aged 18 to 34 years. STUDY DESIGN: Cohort study; Level of evidence, 3. METHODS: A total of 71 patients (29 adolescents, 42 young adults) who had undergone ACI using spheroids were evaluated retrospectively in this multicenter study. For adolescents, the mean defect size was 4.6 ± 2.4 cm(2), and the follow-up range was 3.5 to 8.0 years (mean, 63.3 months). For young adults, the mean defect size was 4.7 ± 1.2 cm(2), and the follow-up range was 3.8 to 4.3 years (mean, 48.4 months). At the follow-up assessment, outcomes were assessed by using validated questionnaires (Knee injury and Osteoarthritis Outcome Score [KOOS], International Knee Documentation Committee [IKDC] subjective knee evaluation form and current health assessment form, and modified Lysholm score), the magnetic resonance observation of cartilage repair tissue (MOCART) score, and if relevant, time to treatment failure. Safety was assessed by the treatment failure rate. RESULTS: No significant difference between the 2 study groups was found for KOOS, IKDC, or MOCART scores, with all patients achieving high functional values. A significant difference was found in the modified Lysholm score, favoring the young adult group over the adolescent group (22.3 ± 1.9 vs 21.0 ± 2.4, respectively; P = .0123). There were no differences between the rates of treatment failure, with 3% in the adolescent group and 5% in the young adult group. CONCLUSION: Third-generation MACI using spheroids is a safe and effective treatment for large cartilage defects of the knee in adolescents at midterm follow-up. Outcomes are comparable with those for young adults after ACI. |
format | Online Article Text |
id | pubmed-6484242 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-64842422019-04-30 Matrix-Associated Autologous Chondrocyte Implantation Is an Effective Treatment at Midterm Follow-up in Adolescents and Young Adults Hoburg, Arnd Löer, Ingo Körsmeier, Konrad Siebold, Rainer Niemeyer, Philipp Fickert, Stefan Ruhnau, Klaus Orthop J Sports Med Article BACKGROUND: Autologous chondrocyte implantation (ACI) is an established method for treating cartilage defects in the knee of adult patients. However, less is known about its effectiveness in adolescents. HYPOTHESIS: Third-generation matrix-associated ACI (MACI) using spheroids (co.don chondrosphere/Spherox) is an effective and safe treatment for articular cartilage defects in adolescents aged 15 to 17 years, with outcomes comparable with those for young adults aged 18 to 34 years. STUDY DESIGN: Cohort study; Level of evidence, 3. METHODS: A total of 71 patients (29 adolescents, 42 young adults) who had undergone ACI using spheroids were evaluated retrospectively in this multicenter study. For adolescents, the mean defect size was 4.6 ± 2.4 cm(2), and the follow-up range was 3.5 to 8.0 years (mean, 63.3 months). For young adults, the mean defect size was 4.7 ± 1.2 cm(2), and the follow-up range was 3.8 to 4.3 years (mean, 48.4 months). At the follow-up assessment, outcomes were assessed by using validated questionnaires (Knee injury and Osteoarthritis Outcome Score [KOOS], International Knee Documentation Committee [IKDC] subjective knee evaluation form and current health assessment form, and modified Lysholm score), the magnetic resonance observation of cartilage repair tissue (MOCART) score, and if relevant, time to treatment failure. Safety was assessed by the treatment failure rate. RESULTS: No significant difference between the 2 study groups was found for KOOS, IKDC, or MOCART scores, with all patients achieving high functional values. A significant difference was found in the modified Lysholm score, favoring the young adult group over the adolescent group (22.3 ± 1.9 vs 21.0 ± 2.4, respectively; P = .0123). There were no differences between the rates of treatment failure, with 3% in the adolescent group and 5% in the young adult group. CONCLUSION: Third-generation MACI using spheroids is a safe and effective treatment for large cartilage defects of the knee in adolescents at midterm follow-up. Outcomes are comparable with those for young adults after ACI. SAGE Publications 2019-04-25 /pmc/articles/PMC6484242/ /pubmed/31041335 http://dx.doi.org/10.1177/2325967119841077 Text en © The Author(s) 2019 http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 License (http://www.creativecommons.org/licenses/by-nc-nd/4.0/) which permits non-commercial use, reproduction and distribution of the work as published without adaptation or alteration, without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Article Hoburg, Arnd Löer, Ingo Körsmeier, Konrad Siebold, Rainer Niemeyer, Philipp Fickert, Stefan Ruhnau, Klaus Matrix-Associated Autologous Chondrocyte Implantation Is an Effective Treatment at Midterm Follow-up in Adolescents and Young Adults |
title | Matrix-Associated Autologous Chondrocyte Implantation Is an Effective Treatment at Midterm Follow-up in Adolescents and Young Adults |
title_full | Matrix-Associated Autologous Chondrocyte Implantation Is an Effective Treatment at Midterm Follow-up in Adolescents and Young Adults |
title_fullStr | Matrix-Associated Autologous Chondrocyte Implantation Is an Effective Treatment at Midterm Follow-up in Adolescents and Young Adults |
title_full_unstemmed | Matrix-Associated Autologous Chondrocyte Implantation Is an Effective Treatment at Midterm Follow-up in Adolescents and Young Adults |
title_short | Matrix-Associated Autologous Chondrocyte Implantation Is an Effective Treatment at Midterm Follow-up in Adolescents and Young Adults |
title_sort | matrix-associated autologous chondrocyte implantation is an effective treatment at midterm follow-up in adolescents and young adults |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6484242/ https://www.ncbi.nlm.nih.gov/pubmed/31041335 http://dx.doi.org/10.1177/2325967119841077 |
work_keys_str_mv | AT hoburgarnd matrixassociatedautologouschondrocyteimplantationisaneffectivetreatmentatmidtermfollowupinadolescentsandyoungadults AT loeringo matrixassociatedautologouschondrocyteimplantationisaneffectivetreatmentatmidtermfollowupinadolescentsandyoungadults AT korsmeierkonrad matrixassociatedautologouschondrocyteimplantationisaneffectivetreatmentatmidtermfollowupinadolescentsandyoungadults AT sieboldrainer matrixassociatedautologouschondrocyteimplantationisaneffectivetreatmentatmidtermfollowupinadolescentsandyoungadults AT niemeyerphilipp matrixassociatedautologouschondrocyteimplantationisaneffectivetreatmentatmidtermfollowupinadolescentsandyoungadults AT fickertstefan matrixassociatedautologouschondrocyteimplantationisaneffectivetreatmentatmidtermfollowupinadolescentsandyoungadults AT ruhnauklaus matrixassociatedautologouschondrocyteimplantationisaneffectivetreatmentatmidtermfollowupinadolescentsandyoungadults |